Saltar al contenido

San Antonio Breast Cancer Symposium

@sabcs.bsky.social did:plc:noiqwwgdlh2wyc5m5shunks3

SABCS is the world's largest gathering of doctors, researchers and scientists sharing state-of-the-art information on experimental biology, etiology, prevention, diagnosis, and therapy for breast cancer and premalignant breast diseases. www.sabcs.org

En Bluesky desde el

Seguidores
1.223
Siguiendo
6
Posts
161
Días en rankings
0

Resumen

San Antonio Breast Cancer Symposium (@sabcs.bsky.social) es un usuario de Bluesky que se unió el 20 noviembre 2024. Tiene 1.223 seguidores, sigue a 6 cuentas y ha publicado 161 posts.

Apariciones en rankings

Los mejores días en que los posts de esta cuenta entraron en la lista diaria de Debya.

Esta cuenta aún no ha aparecido en un ranking diario.

Posts que le gustaron recientemente

Me gusta públicos de la red Bluesky.

  • Stacey Tinianov, MPH@coffeemommy.bsky.social

    Mid-week into hot-off-the-press research results at the annual @sabcs.bsky.social Grateful to be sharing space and hugs with fellow advocates and colleagues 💗 #SABCS25

    Ver post
  • Yale Cancer Center@yalecancer.bsky.social

    @ncasasanta.bsky.social presents data at #SABCS25: In advanced #breastcancer, genomic profiling shows younger women more frequently have BRCA1/2, TP53, HRD, and PD-L1 alterations, while older women more often exhibit ESR1, PIK3CA, CDH1, and higher TMB. @sabcs.bsky.social @oncoalert.bsky.social

    Ver post
  • Yale Cancer Center@yalecancer.bsky.social

    Dr. Guannan Gong shares how an #AI-driven patient-matching system improved ID of eligible patients for #breastcancer trials + increased representation of under-enrolled groups. #SABCS25 @maryamlustberg.bsky.social @sabcs.bsky.social @oncoalert.bsky.social

    Ver post
  • Yale Cancer Center@yalecancer.bsky.social

    New research from Dr. Lajos Pusztai #SABCS25 shows RNA levels of ESR1, PGR closely match traditional estrogen receptor/progesterone receptor test results in #breastcancer. @foundationmedicine.bsky.social @sabcs.bsky.social @oncoalert.bsky.social

    Ver post
  • Yale Cancer Center@yalecancer.bsky.social

    Dr. Mariya Rozenblit highlights how C1D15 DiviTum® TKa levels can uncover early adherence issues or drug interactions during CDK4/6 inhibitor therapy. #SABCS25 Takeaway: DiviTum® TKa is a practical early biomarker to optimize breast cancer treatment outcomes. @sabcs.bsky.social

    Ver post

Inicia sesión para ver más

Cuentas que bloquea

En Bluesky los bloqueos son registros públicos.

Esta cuenta no bloquea a nadie.